within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AH03_Peramivir;

model Peramivir
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 2.8055555555555555e-06,
    adminDuration = 600,
    adminMass = 600 / 1000000,
    adminCount = 1,
    Vd = 0.01256,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.00813,
    k12 = 4.611111111111111e-06,
    k21 = 4.611111111111111e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Peramivir</td></tr><tr><td>ATC code:</td><td>J05AH03</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>600</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>12.56</td><td>L</td></tr>
    <tr><td>clearance:</td><td>10.1</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Peramivir is a neuraminidase inhibitor antiviral drug used for the treatment of influenza. It is administered primarily as a single-dose intravenous infusion for adults with acute uncomplicated influenza. Peramivir is approved for use in the United States and several other countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects after a single 600 mg intravenous dose.</p><h4>References</h4><ol><li><p>Matsuo, Y, et al., &amp; Wajima, T (2015). Population pharmacokinetics of peramivir in healthy volunteers and influenza patients. <i>Antimicrobial agents and chemotherapy</i> 59(11) 6755–6762. DOI:<a href=\"https://doi.org/10.1128/AAC.00799-15\">10.1128/AAC.00799-15</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26282420/\">https://pubmed.ncbi.nlm.nih.gov/26282420</a></p></li><li><p>Zhang, D, et al., &amp; Liu, H (2015). Pharmacokinetics of peramivir after single intravenous doses in healthy Chinese subjects. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 45(3) 239–243. DOI:<a href=\"https://doi.org/10.3109/00498254.2014.960907\">10.3109/00498254.2014.960907</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25231091/\">https://pubmed.ncbi.nlm.nih.gov/25231091</a></p></li><li><p>Sugaya, N, et al., &amp; Takahashi, T (2012). Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection. <i>Antimicrobial agents and chemotherapy</i> 56(1) 369–377. DOI:<a href=\"https://doi.org/10.1128/AAC.00132-11\">10.1128/AAC.00132-11</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22024821/\">https://pubmed.ncbi.nlm.nih.gov/22024821</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J05AH03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Peramivir;
